- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Zeneca uses contract reps
Zeneca Pharmaceuticals, Wilmington, DE, is recruiting and training 250 new contract sales reps who will focus their efforts on reaching cardiovascular physicians.
Zeneca Pharmaceuticals, Wilmington, DE, is recruiting and training 250 new contract sales reps who will focus their efforts on reaching cardiovascular physicians.
"We recognized the need to increase our representation in the field," said Bill Simpson, national business director.
Zeneca had several reasons for using a contract sales force instead of expanding its permanent roster, Simpson said.
First, the company didn't want to tie up its field sales managers and reps in time-consuming recruitment efforts that could affect their sales numbers.
Second, the company said it only anticipates to have a shortage in its detailing muscle for the next two years. "A contract sales force lets us to 'staff up' or 'staff down' without disrupting the full-time field force," Simpson said.
Third, Zeneca wanted to reinforce existing field territories without changing the relationships its full-time reps have with physicians.
The process
The addition of the new reps marks the first time Zeneca has used a contract sales force.
HealthCare Promotions, Middlesex, NJ, is hiring and managing the new contract team. Zeneca's sales training department will coordinate the training for the new reps to ensure that their product knowledge and selling skills are consistent with those of the existing field force.
The company said up to 100 of the contract reps may be hired for permanent positions on its 1,200-rep field force.
The contract sales force will work three days a week promoting Zeneca's cardiovascular products, Zestril® (lisinopril) and Sular® (nisoldipine).
Early last year, Zeneca supplemented its field team by expanding its comprehensive care and oncology care sales forces. The company added about 170 people to its comprehensive care team and 40 people to its oncology force.
In 1996, the company introduced seven new products: Sular; Arimidex® (anastrozole); Zoladex® (goserelin acetate implant) three-month depot; the modified formulation of Diprivan® (propofol) Injectable Emulsion; Kadian® (morphine sulfate sustained release); Merrem® (meropenem); and Accolate® (zafirlukast).
The company said two of its product candidates could be approved this year: Seroquel⢠(quetiapine), an antipsychotic, and Zomig⢠(zolmitriptan), a migraine drug. PR
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.
